183 related articles for article (PubMed ID: 23604105)
1. Antibody-peptide-MHC fusion conjugates target non-cognate T cells to kill tumour cells.
King BC; Hamblin AD; Savage PM; Douglas LR; Hansen TH; French RR; Johnson PW; Glennie MJ
Cancer Immunol Immunother; 2013 Jun; 62(6):1093-105. PubMed ID: 23604105
[TBL] [Abstract][Full Text] [Related]
2. DuoBody-CD3xCD20 induces potent T-cell-mediated killing of malignant B cells in preclinical models and provides opportunities for subcutaneous dosing.
Engelberts PJ; Hiemstra IH; de Jong B; Schuurhuis DH; Meesters J; Beltran Hernandez I; Oostindie SC; Neijssen J; van den Brink EN; Horbach GJ; Verploegen S; Labrijn AF; Salcedo T; Schuurman J; Parren PWHI; Breij ECW
EBioMedicine; 2020 Feb; 52():102625. PubMed ID: 31981978
[TBL] [Abstract][Full Text] [Related]
3. In vivo targeting of an anti-tumor antibody coupled to antigenic MHC class I complexes induces specific growth inhibition and regression of established syngeneic tumor grafts.
Donda A; Cesson V; Mach JP; Corradin G; Primus FJ; Robert B
Cancer Immun; 2003 Aug; 3():11. PubMed ID: 12916958
[TBL] [Abstract][Full Text] [Related]
4. Trispecific F(ab')3 derivatives that use cooperative signaling via the TCR/CD3 complex and CD2 to activate and redirect resting cytotoxic T cells.
Tutt A; Stevenson GT; Glennie MJ
J Immunol; 1991 Jul; 147(1):60-9. PubMed ID: 1675655
[TBL] [Abstract][Full Text] [Related]
5. Tetramer-blocking assay for defining antigen-specific cytotoxic T lymphocytes using peptide-MHC tetramer.
Yokouchi H; Chamoto K; Wakita D; Noguchi D; Yamazaki K; Dosaka-Akita H; Nishimura M; Ikeda H; Nishimura T
Cancer Sci; 2006 Feb; 97(2):148-54. PubMed ID: 16441426
[TBL] [Abstract][Full Text] [Related]
6. Affinity thresholds for naive CD8+ CTL activation by peptides and engineered influenza A viruses.
Denton AE; Wesselingh R; Gras S; Guillonneau C; Olson MR; Mintern JD; Zeng W; Jackson DC; Rossjohn J; Hodgkin PD; Doherty PC; Turner SJ
J Immunol; 2011 Dec; 187(11):5733-44. PubMed ID: 22039305
[TBL] [Abstract][Full Text] [Related]
7. Antibody-conjugated MHC class I tetramers can target tumor cells for specific lysis by T lymphocytes.
Robert B; Guillaume P; Luescher I; Romero P; Mach JP
Eur J Immunol; 2000 Nov; 30(11):3165-70. PubMed ID: 11093131
[TBL] [Abstract][Full Text] [Related]
8. Increased lysis of patient CD10-positive leukemic cells by T cells coated with anti-CD3 Fab' antibody cross-linked to anti-CD10 Fab' antibody.
Oshimi K; Seto T; Oshimi Y; Masuda M; Okumura K; Mizoguchi H
Blood; 1991 Mar; 77(5):1044-9. PubMed ID: 1825287
[TBL] [Abstract][Full Text] [Related]
9. Lysis of murine B lymphoma cells by transgenic phagocytes via a human Fc gamma RI x murine MHC class II bispecific antibody.
Heijnen IA; Glennie MJ; van de Winkel JG
Cancer Immunol Immunother; 1997; 45(3-4):166-70. PubMed ID: 9435865
[TBL] [Abstract][Full Text] [Related]
10. Antibody-antigen-adjuvant conjugates enable co-delivery of antigen and adjuvant to dendritic cells in cis but only have partial targeting specificity.
Kreutz M; Giquel B; Hu Q; Abuknesha R; Uematsu S; Akira S; Nestle FO; Diebold SS
PLoS One; 2012; 7(7):e40208. PubMed ID: 22808118
[TBL] [Abstract][Full Text] [Related]
11. A T-cell-engaging B7-H4/CD3-bispecific Fab-scFv Antibody Targets Human Breast Cancer.
Iizuka A; Nonomura C; Ashizawa T; Kondou R; Ohshima K; Sugino T; Mitsuya K; Hayashi N; Nakasu Y; Maruyama K; Yamaguchi K; Akiyama Y
Clin Cancer Res; 2019 May; 25(9):2925-2934. PubMed ID: 30737243
[TBL] [Abstract][Full Text] [Related]
12. A bispecific T cell engager targeting Glypican-1 redirects T cell cytolytic activity to kill prostate cancer cells.
Lund ME; Howard CB; Thurecht KJ; Campbell DH; Mahler SM; Walsh BJ
BMC Cancer; 2020 Dec; 20(1):1214. PubMed ID: 33302918
[TBL] [Abstract][Full Text] [Related]
13. A novel, native-format bispecific antibody triggering T-cell killing of B-cells is robustly active in mouse tumor models and cynomolgus monkeys.
Smith EJ; Olson K; Haber LJ; Varghese B; Duramad P; Tustian AD; Oyejide A; Kirshner JR; Canova L; Menon J; Principio J; MacDonald D; Kantrowitz J; Papadopoulos N; Stahl N; Yancopoulos GD; Thurston G; Davis S
Sci Rep; 2015 Dec; 5():17943. PubMed ID: 26659273
[TBL] [Abstract][Full Text] [Related]
14. Active antiviral T-lymphocyte response can be redirected against tumor cells by antitumor antibody x MHC/viral peptide conjugates.
Cesson V; Stirnemann K; Robert B; Luescher I; Filleron T; Corradin G; Mach JP; Donda A
Clin Cancer Res; 2006 Dec; 12(24):7422-30. PubMed ID: 17189415
[TBL] [Abstract][Full Text] [Related]
15. Cytotoxic T-cells specific for natural IgE peptides downregulate IgE production.
Chen SS; Gong J; Yang YM; Oettgen H; Zanetti M
Cell Immunol; 2005 Jan; 233(1):11-22. PubMed ID: 15913585
[TBL] [Abstract][Full Text] [Related]
16. Sensitization of tumour cells to lysis by virus-specific CTL using antibody-targeted MHC class I/peptide complexes.
Ogg GS; Dunbar PR; Cerundolo V; McMichael AJ; Lemoine NR; Savage P
Br J Cancer; 2000 Mar; 82(5):1058-62. PubMed ID: 10737389
[TBL] [Abstract][Full Text] [Related]
17. [Study on the construction and expression of the human 4-1BBL extracellular domain/anti-CD20 Fab' fusion protein].
Jiang W; Xiong D; Liu F; Guo H; Su Y; Lü J; Yang C
Sheng Wu Gong Cheng Xue Bao; 2008 Mar; 24(3):376-80. PubMed ID: 18589811
[TBL] [Abstract][Full Text] [Related]
18. Anti-CD3-based bispecific antibody designed for therapy of human B-cell malignancy can induce T-cell activation by antigen-dependent and antigen-independent mechanisms.
Link BK; Kostelny SA; Cole MS; Fusselman WP; Tso JY; Weiner GJ
Int J Cancer; 1998 Jul; 77(2):251-6. PubMed ID: 9650561
[TBL] [Abstract][Full Text] [Related]
19. Tumor-infiltrating lymphocytes can be activated in situ by using in vivo activants plus F(ab')2 bispecific antibodies.
Thibault C; Nelson H; Chapoval AI
Int J Cancer; 1996 Jul; 67(2):232-7. PubMed ID: 8760593
[TBL] [Abstract][Full Text] [Related]
20. Generating bispecific human IgG1 and IgG2 antibodies from any antibody pair.
Strop P; Ho WH; Boustany LM; Abdiche YN; Lindquist KC; Farias SE; Rickert M; Appah CT; Pascua E; Radcliffe T; Sutton J; Chaparro-Riggers J; Chen W; Casas MG; Chin SM; Wong OK; Liu SH; Vergara G; Shelton D; Rajpal A; Pons J
J Mol Biol; 2012 Jul; 420(3):204-19. PubMed ID: 22543237
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
